LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akciju saraksts・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

24.33 3.18

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

24.17

Max

24.37

Galvenie mērījumi
By Trading Economics
Ienākumi	675K 53M
Pārdošana	1.8M 148M
P/E Sektora vidējais	14.298 121.746
Peļņas marža	35.57
Darbinieki	181
EBITDA	1.7M 80M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+48.31% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 25. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	381M 3B
Iepriekšējā atvēršanas cena	21.15
Iepriekšējā slēgšanas cena	24.33

Ziņu noskaņojums

By Acuity

29%

71%

59 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

N/A / 24.28 Atbalsts un pretestība

Catalyst Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. febr. 16:32 UTC

Peļņas

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026. g. 14. febr. 22:02 UTC

Peļņas

Looking for Dividends? Consider Europe. -- Barrons.com

2026. g. 14. febr. 09:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 13. febr. 21:57 UTC

Peļņas

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026. g. 13. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 13. febr. 21:20 UTC

Peļņas

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026. g. 13. febr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Dollar Pares Down Early Losses -- Market Talk

2026. g. 13. febr. 20:39 UTC

Tirgus saruna

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026. g. 13. febr. 20:28 UTC

Tirgus saruna

Oil Settles Week Lower -- Market Talk

2026. g. 13. febr. 19:51 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:29 UTC

Peļņas

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026. g. 13. febr. 18:18 UTC

Iegādes, apvienošanās, pārņemšana

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026. g. 13. febr. 17:52 UTC

Peļņas

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026. g. 13. febr. 17:16 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 17:10 UTC

Iegādes, apvienošanās, pārņemšana

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026. g. 13. febr. 16:59 UTC

Peļņas

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026. g. 13. febr. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026. g. 13. febr. 16:11 UTC

Peļņas

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026. g. 13. febr. 16:07 UTC

Tirgus saruna

Hungarian Forint Could Rise Further -- Market Talk

2026. g. 13. febr. 15:54 UTC

Peļņas

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026. g. 13. febr. 15:26 UTC

Tirgus saruna

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026. g. 13. febr. 15:01 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026. g. 13. febr. 15:00 UTC

Peļņas

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026. g. 13. febr. 14:50 UTC

Tirgus saruna

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026. g. 13. febr. 14:44 UTC

Peļņas

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026. g. 13. febr. 14:22 UTC

Tirgus saruna

Peļņas

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Catalyst Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

48.31% augšup

Prognoze 12 mēnešiem

Vidējais 35 USD 48.31%

Augstākais 35 USD

Zemākais 35 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Catalyst Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Catalyst Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 24.28Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Noskaņojums

By Acuity

59 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.